Neurocrine Biosciences, Inc. (NBIX)
USD 90.49
(-0.25%)
USD 90.49
(-0.25%)
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2023 | 258.3 Million USD | 176.26% |
| 2022 | 93.5 Million USD | -78.77% |
| 2021 | 440.4 Million USD | 6.82% |
| 2020 | 412.3 Million USD | 375.55% |
| 2019 | 86.7 Million USD | -77.68% |
| 2018 | 388.49 Million USD | 5.11% |
| 2017 | 369.61 Million USD | 0.0% |
| 2016 | - USD | 0.0% |
| 2015 | - USD | 0.0% |
| 2014 | - USD | 0.0% |
| 2013 | - USD | 0.0% |
| 2012 | - USD | 0.0% |
| 2011 | - USD | 0.0% |
| 2010 | - USD | -100.0% |
| 2009 | 7.24 Million USD | 0.0% |
| 2008 | - USD | -100.0% |
| 2007 | 108.74 Million USD | 121.24% |
| 2006 | 49.15 Million USD | -8.28% |
| 2005 | 53.59 Million USD | -9.86% |
| 2004 | 59.45 Million USD | 83.08% |
| 2003 | 32.47 Million USD | 515.37% |
| 2002 | 5.27 Million USD | 46.58% |
| 2001 | 3.6 Million USD | 57.69% |
| 2000 | 2.28 Million USD | 8.71% |
| 1999 | 2.1 Million USD | -4.55% |
| 1998 | 2.2 Million USD | 214.29% |
| 1997 | 700 Thousand USD | -12.5% |
| 1996 | 800 Thousand USD | 0.0% |
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2024 Q2 | 256.2 Million USD | 0.0% |
| 2024 Q1 | 252.9 Million USD | 0.0% |
| 2024 Q3 | 251.4 Million USD | 0.0% |
| 2023 Q2 | 89.1 Million USD | -65.72% |
| 2023 Q1 | 259.9 Million USD | 177.97% |
| 2023 Q3 | 85.9 Million USD | -3.59% |
| 2023 FY | 258.3 Million USD | 176.26% |
| 2023 Q4 | 258.3 Million USD | 200.7% |
| 2022 FY | 93.5 Million USD | -78.77% |
| 2022 Q2 | 268.6 Million USD | -44.06% |
| 2022 Q3 | 96.6 Million USD | -64.04% |
| 2022 Q1 | 480.2 Million USD | 9.04% |
| 2022 Q4 | 93.5 Million USD | -3.21% |
| 2021 Q3 | 437.1 Million USD | 0.41% |
| 2021 Q2 | 435.3 Million USD | 1.35% |
| 2021 Q1 | 429.5 Million USD | 4.17% |
| 2021 Q4 | 440.4 Million USD | 0.75% |
| 2021 FY | 440.4 Million USD | 6.82% |
| 2020 Q3 | 83 Million USD | -1.54% |
| 2020 Q1 | 499.7 Million USD | 476.36% |
| 2020 Q2 | 84.3 Million USD | -83.13% |
| 2020 FY | 412.3 Million USD | 375.55% |
| 2020 Q4 | 412.3 Million USD | 396.75% |
| 2019 Q3 | 478.07 Million USD | 2.89% |
| 2019 Q1 | 460.58 Million USD | 18.56% |
| 2019 Q4 | 86.7 Million USD | -81.86% |
| 2019 Q2 | 464.65 Million USD | 0.88% |
| 2019 FY | 86.7 Million USD | -77.68% |
| 2018 Q1 | 374.2 Million USD | 1.24% |
| 2018 FY | 388.49 Million USD | 5.11% |
| 2018 Q4 | 388.49 Million USD | 1.26% |
| 2018 Q3 | 383.64 Million USD | 1.26% |
| 2018 Q2 | 378.88 Million USD | 1.25% |
| 2017 FY | 369.61 Million USD | 0.0% |
| 2017 Q4 | 369.61 Million USD | 1.23% |
| 2017 Q3 | 365.11 Million USD | 1.23% |
| 2017 Q2 | 360.68 Million USD | 0.0% |
| 2017 Q1 | - USD | 0.0% |
| 2016 Q3 | - USD | 0.0% |
| 2016 Q4 | - USD | 0.0% |
| 2016 FY | - USD | 0.0% |
| 2016 Q2 | - USD | 0.0% |
| 2016 Q1 | - USD | 0.0% |
| 2015 Q1 | - USD | 0.0% |
| 2015 FY | - USD | 0.0% |
| 2015 Q2 | - USD | 0.0% |
| 2015 Q3 | - USD | 0.0% |
| 2015 Q4 | - USD | 0.0% |
| 2014 Q3 | - USD | 0.0% |
| 2014 Q4 | - USD | 0.0% |
| 2014 FY | - USD | 0.0% |
| 2014 Q1 | - USD | 0.0% |
| 2014 Q2 | - USD | 0.0% |
| 2013 FY | - USD | 0.0% |
| 2013 Q4 | - USD | 0.0% |
| 2013 Q1 | - USD | 0.0% |
| 2013 Q2 | - USD | 0.0% |
| 2013 Q3 | - USD | 0.0% |
| 2012 Q2 | - USD | 0.0% |
| 2012 FY | - USD | 0.0% |
| 2012 Q1 | - USD | 0.0% |
| 2012 Q4 | - USD | 0.0% |
| 2012 Q3 | - USD | 0.0% |
| 2011 Q3 | - USD | 0.0% |
| 2011 Q1 | - USD | 0.0% |
| 2011 FY | - USD | 0.0% |
| 2011 Q4 | - USD | 0.0% |
| 2011 Q2 | - USD | 0.0% |
| 2010 Q1 | 6.16 Million USD | -14.89% |
| 2010 FY | - USD | -100.0% |
| 2010 Q4 | - USD | -100.0% |
| 2010 Q3 | 4.48 Million USD | -11.9% |
| 2010 Q2 | 5.09 Million USD | -17.36% |
| 2009 Q3 | 8.37 Million USD | 204.65% |
| 2009 Q1 | 3.01 Million USD | 0.0% |
| 2009 Q2 | 2.75 Million USD | -8.82% |
| 2009 FY | 7.24 Million USD | 0.0% |
| 2009 Q4 | 7.24 Million USD | -13.57% |
| 2008 Q2 | 108.74 Million USD | 0.0% |
| 2008 Q3 | 108.74 Million USD | 0.0% |
| 2008 Q4 | - USD | -100.0% |
| 2008 FY | - USD | -100.0% |
| 2008 Q1 | 108.74 Million USD | 0.0% |
| 2007 Q2 | 47.93 Million USD | -1.22% |
| 2007 Q4 | 108.74 Million USD | 129.24% |
| 2007 Q1 | 48.52 Million USD | -1.27% |
| 2007 FY | 108.74 Million USD | 121.24% |
| 2007 Q3 | 47.43 Million USD | -1.03% |
| 2006 Q2 | 51.2 Million USD | -2.29% |
| 2006 Q4 | 49.15 Million USD | -1.95% |
| 2006 FY | 49.15 Million USD | -8.28% |
| 2006 Q1 | 52.4 Million USD | -2.21% |
| 2006 Q3 | 50.12 Million USD | -2.1% |
| 2005 Q3 | 54.94 Million USD | -2.59% |
| 2005 Q4 | 53.59 Million USD | -2.46% |
| 2005 Q2 | 56.4 Million USD | -2.67% |
| 2005 Q1 | 57.95 Million USD | -2.53% |
| 2005 FY | 53.59 Million USD | -9.86% |
| 2004 Q1 | 43.09 Million USD | 32.71% |
| 2004 Q4 | 59.45 Million USD | -7.03% |
| 2004 Q3 | 63.94 Million USD | 16.41% |
| 2004 Q2 | 54.93 Million USD | 27.47% |
| 2004 FY | 59.45 Million USD | 83.08% |
| 2003 Q2 | 19.12 Million USD | 256.57% |
| 2003 Q3 | 19.1 Million USD | -0.09% |
| 2003 Q4 | 32.47 Million USD | 69.97% |
| 2003 FY | 32.47 Million USD | 515.37% |
| 2003 Q1 | 5.36 Million USD | 1.63% |
| 2002 Q3 | 4.47 Million USD | 23.05% |
| 2002 FY | 5.27 Million USD | 46.58% |
| 2002 Q4 | 5.27 Million USD | 17.97% |
| 2002 Q1 | 3.22 Million USD | -10.33% |
| 2002 Q2 | 3.63 Million USD | 12.61% |
| 2001 Q2 | 2.42 Million USD | 22.62% |
| 2001 Q4 | 3.6 Million USD | 76.3% |
| 2001 Q3 | 2.04 Million USD | -15.72% |
| 2001 Q1 | 1.97 Million USD | -13.45% |
| 2001 FY | 3.6 Million USD | 57.69% |
| 2000 Q1 | 1.88 Million USD | -10.29% |
| 2000 Q2 | 1.62 Million USD | -13.64% |
| 2000 FY | 2.28 Million USD | 8.71% |
| 2000 Q3 | 1.91 Million USD | 17.39% |
| 2000 Q4 | 2.28 Million USD | 19.53% |
| 1999 Q1 | 2.1 Million USD | -4.55% |
| 1999 FY | 2.1 Million USD | -4.55% |
| 1999 Q2 | 2.3 Million USD | 9.52% |
| 1999 Q3 | 2.2 Million USD | -4.35% |
| 1999 Q4 | 2.1 Million USD | -4.55% |
| 1998 FY | 2.2 Million USD | 214.29% |
| 1998 Q1 | - USD | -100.0% |
| 1998 Q4 | 2.2 Million USD | 0.0% |
| 1998 Q3 | - USD | 0.0% |
| 1998 Q2 | - USD | 0.0% |
| 1997 Q4 | 700 Thousand USD | 0.0% |
| 1997 Q3 | - USD | 0.0% |
| 1997 FY | 700 Thousand USD | -12.5% |
| 1997 Q2 | - USD | 0.0% |
| 1997 Q1 | - USD | -100.0% |
| 1996 FY | 800 Thousand USD | 0.0% |
| 1996 Q4 | 800 Thousand USD | 0.0% |
| 1996 Q1 | 1.4 Million USD | 0.0% |
| 1996 Q2 | - USD | -100.0% |
| 1996 Q3 | - USD | 0.0% |
| Name | Long Term Debt | Long Term Debt Difference |
|---|---|---|
| Bright Green Corporation | 201.78 Thousand USD | -127908.802% |
| Alpha Teknova, Inc. | 13.25 Million USD | -1849.287% |
| ANI Pharmaceuticals, Inc. | 309.66 Million USD | 16.588% |
| Aquestive Therapeutics, Inc. | 91.07 Million USD | -183.609% |
| Collegium Pharmaceutical, Inc. | 489.96 Million USD | 47.282% |
| Cosmos Health Inc. | 3.03 Million USD | -8409.752% |
| Journey Medical Corporation | 14.62 Million USD | -1666.516% |
| Embecta Corp. | 1.62 Billion USD | 84.109% |
| Esperion Therapeutics, Inc. | 501.54 Million USD | 48.499% |
| Dynavax Technologies Corporation | 252.41 Million USD | -2.33% |
| Intra-Cellular Therapies, Inc. | 13.32 Million USD | -1838.316% |
| Pacira BioSciences, Inc. | 513.79 Million USD | 49.727% |
| PainReform Ltd. | 30 Thousand USD | -860900.0% |
| Sunshine Biopharma, Inc. | 539.03 Thousand USD | -47818.966% |
| Sunshine Biopharma, Inc. | 539.03 Thousand USD | -47818.966% |
| SCYNEXIS, Inc. | 12.15 Million USD | -2024.352% |
| Safety Shot Inc | 304.9 Thousand USD | -84614.356% |
| China SXT Pharmaceuticals, Inc. | 117.12 Thousand USD | -220426.087% |
| Procaps Group, S.A. | 28.41 Million USD | -809.187% |
| Theratechnologies Inc. | 51.26 Million USD | -403.892% |
| Harrow Health, Inc. | 183.17 Million USD | -41.015% |
| Sonoma Pharmaceuticals, Inc. | 87 Thousand USD | -296796.552% |
| Biofrontera Inc. | 804 Thousand USD | -32026.866% |
| DURECT Corporation | 2.7 Million USD | -9459.585% |
| Supernus Pharmaceuticals, Inc. | 33.19 Million USD | -678.106% |
| Cronos Group Inc. | 1.55 Million USD | -16468.313% |
| OptiNose, Inc. | 611 Thousand USD | -42174.959% |
| Ironwood Pharmaceuticals, Inc. | 498.3 Million USD | 48.165% |
| Kala Pharmaceuticals, Inc. | 34.19 Million USD | -655.484% |
| RedHill Biopharma Ltd. | 455 Thousand USD | -56669.231% |
| Organogenesis Holdings Inc. | 60.74 Million USD | -325.22% |
| Guardion Health Sciences, Inc. | - USD | -Infinity% |
| Cumberland Pharmaceuticals Inc. | 12.78 Million USD | -1920.472% |
| Radius Health, Inc. | 339.66 Million USD | 23.954% |
| Universe Pharmaceuticals INC | - USD | -Infinity% |
| ProPhase Labs, Inc. | 10.25 Million USD | -2418.035% |
| Phibro Animal Health Corporation | 458.28 Million USD | 43.638% |
| Procaps Group S.A. | 28.41 Million USD | -809.187% |
| Alvotech | 1.02 Billion USD | 74.868% |
| TherapeuticsMD, Inc. | 6.53 Million USD | -3854.378% |
| Viatris Inc. | 16.18 Billion USD | 98.404% |
| Rockwell Medical, Inc. | 8.29 Million USD | -3014.675% |
| Aytu BioPharma, Inc. | 10.87 Million USD | -2274.736% |
| SIGA Technologies, Inc. | 335.99 Thousand USD | -76777.059% |
| Tilray Brands, Inc. | 287.93 Million USD | 10.292% |
| Lifecore Biomedical, Inc. | 120.51 Million USD | -114.339% |
| Shineco, Inc. | 10.01 Million USD | -2478.531% |
| PetIQ, Inc. | 437.82 Million USD | 41.003% |
| Regencell Bioscience Holdings Limited | - USD | -Infinity% |
| Incannex Healthcare Limited | 210 Thousand USD | -122900.0% |
| Alimera Sciences, Inc. | 64.48 Million USD | -300.533% |
| Silver Spike Investment Corp. | - USD | -Infinity% |
| Assertio Holdings, Inc. | 38.51 Million USD | -570.665% |
| Shuttle Pharmaceuticals Holdings, Inc. | 135.08 Thousand USD | -191107.278% |
| Petros Pharmaceuticals, Inc. | 6.85 Million USD | -3666.754% |
| Clever Leaves Holdings Inc. | 720 Thousand USD | -35775.0% |
| Cyclo Therapeutics, Inc. | 22.48 Thousand USD | -1148716.936% |
| Avadel Pharmaceuticals plc | 32.75 Million USD | -688.462% |
| Hempacco Co., Inc. | 5.93 Million USD | -4255.083% |
| Talphera, Inc. | - USD | -Infinity% |
| Alvotech | 1.02 Billion USD | 74.868% |
| Eagle Pharmaceuticals, Inc. | 56.21 Million USD | -359.478% |
| Lantheus Holdings, Inc. | 616.12 Million USD | 58.077% |
| Currenc Group, Inc. | 2.5 Million USD | -10203.258% |
| Kamada Ltd. | 7.43 Million USD | -3372.708% |
| Indivior PLC | 235.66 Million USD | -9.604% |
| Evoke Pharma, Inc. | 5 Million USD | -5066.0% |
| Flora Growth Corp. | 942 Thousand USD | -27320.382% |
| Cyclo Therapeutics, Inc. | 22.48 Thousand USD | -1148716.936% |
| Evolus, Inc. | 120.35 Million USD | -114.608% |
| HUTCHMED (China) Limited | 48.18 Million USD | -436.014% |
| Amphastar Pharmaceuticals, Inc. | 589.19 Million USD | 56.161% |
| Akanda Corp. | 2.49 Million USD | -10243.771% |